The ratio of CD44+ CD62L+ central memory (TCM) cells was higher in hepatocellular carcinoma (HCC) tumors from MYC‐ON mice as well as in colon tumors from CT‐26 allograft mice after DU101 or DU102 treatment in comparison with DMSO treatment (Figure S7l–o, Supporting Information). This evidence concerns the gene CD44 and hepatocellular carcinoma.